Shionogi Company Limited

Shin-Etsu Chemical Co., Ltd.

Yoshio Doi

Noboru Hoshi

Yasushi Takagishi

Izumi Saitoh

Shohei Egawa

Kaori Ikeda

Shigeru Kido

Kiichiro Ohsuga

Kanji Aita

Shionogi & Co, Ltd

A pharmaceutical preparation for the treatment of tinea pedis, containing as basic components about 0.1% to about 2.5% of croconazole hydrochloride and about 1%-15% of an ethyl acrylate-methyl methacrylate copolymer in an aqueous alcohol, and if necessary, about 0.1% to about 2.5% of a thickening agent and/or a plasticizer.

Pharmaceutical preparation for tinea pedis

External preparations consisting essentially of about 0.1% to about 5% of tocopherol acetate and/or about 0.05% to about 0.3% of glycyrrhetinic acid, about 1% to about 15% of a methacrylic acid-ethyl acrylate copolymer, and about 0.2% to about 3% of a thickening agent in an alcoholic solvent, wherein said copolymer is characterized by that the monomer ratio of ethyl acrylate to methacrylic acid is within a range from 75/25 to 95/5, with residual monomer being 50 ppm or less and with practically no surfactants.

External preparation of vitamin-E

Film-formation-type antifungal preparations for external application, consisting essentially of about 0.1% to about 1.5% of tolnaphtate, about 10% to about 20% of a dimethylaminoethyl methacrylate-methacrylic acid ester copolymer and 0.5% to about 10% of a medium chain fatty acid ester in an alcoholic solvent but containing practically no water.

Film-formation-type antifungal preparation

The invention provides a novel means for the administration of a therapeutically effective ingredient in the form of a rectally applicable medicament capsule, in which the otherwise unavoidable extreme variation in the absorbability of the effective ingredient among the individuals rectally treated with the capsules is minimized. It has been unexpectedly found that, when the effective ingredient is contained in the capsule in the form of a liquid medicine, the osmotic pressure of the liquid content plays a very essential role in the absorption of the effective ingredient through the rectum and the variation in the absorbability of the effective ingredient among the individuals can be minimized when the osmotic pressure of the liquid content is substantially higher than the osmotic pressure of the rectal fluid with which the capsules are contacted.

Medicament capsules for rectal application

The invention provides a novel and efficient means for the administration of a therapeutically effective ingredient by rectal application in the form of a medicament capsule encapsulating the effective ingredient. The medicament capsule according to the invention is formed of a hard capsule shell made of a mixed ester of a cellulose ether, e.g. alkyl-, hydroxyalkyl- and hydroxyalkyl alkylcelluloses, esterified with aliphatic monacyl groups and acidic succinyl groups. When the capsule is inserted into the rectum, the capsule shell is disintegrated and the rectally absorbable effective ingredient is readily and smoothly released into the rectum and absorbed to exhibit therapeutical effects as efficiently as with conventional suppositories.

The invention provides a novel means for overcoming the problem of undue and irregular delay in the exhibition of the effect of medicine when a patient is administrated with an enterosoluble hard-capsulated medicament. The unexpected discovery that the key parameter ruling the smooth transfer of an enterosoluble capsule from the stomach to the intestinal canals is the overall specific gravity of the capsule has led to the establishment of the invention which proposes an enterosoluble hard-capsulated medicament having an overall specific gravity of at least 1.05 or, preferably, at least 1.10.

Growing community of inventors

Ibaraki, Japan

Yoshio Doi